Bookmark and Share

Simulations Plus (SLP) Reports First Quarter FY2011 Financial Results

Jan. 14, 2011 (Business Wire) — Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today reported financial results for its first quarter of fiscal year 2011 ended November 30, 2010 (1QFY11).

1QFY11 highlights compared with 1QFY10:

  • Consolidated revenues up 15.4% to record $2.811 million from $2.437 million
  • Pharmaceutical software and services revenues up 18.2% to $2.050 million from $1.735 million
  • Words+ subsidiary revenues up 8.3% to $761,000 from $702,000
  • Gross profit up 13.1% to $2.070 million from $1.830 million
  • SG&A increased 5.8% to $1.062 million from $1.004 million
  • R&D expenditures decreased 14.4% to $395,000 from $462,000
  • Income before income taxes up 24.7% to $0.825 million from $0.661 million
  • Net income up 32.0% to $568,000 from $430,000
  • Diluted earnings per share up 34% to $0.0343 from $0.0256

Ms. Momoko Beran, chief financial officer of Simulations Plus, said, “We’re pleased to report these results that show continued strong performance in both business units. Cash at the end of 1QFY11 was $8.873 million compared to $7.973 million at the end of 1QFY10, and compared to $9.63 million at the beginning of the quarter. We used $1.190 million of our cash to repurchase 397,680 shares during the first quarter. Although we incurred this expenditure, shareholders’ equity increased 15.4% to $12.482 million compared to $10.812 million in 1QFY10.”

Walt Woltosz, chairman and chief executive officer of Simulations Plus, added, “This is yet another record first quarter for both revenues and earnings. We’ve experienced steady growth and new record quarter-over-quarter performance for a number of years, including through the recent global downturn for so many other businesses. We believe our emphasis on providing the very best in our product areas, an aggressive marketing and sales program, strong customer support, and frugal expense management have been the keys to this success. We continue to seek accretive acquisitions, and while we’ve investigated a number of them in the past couple of years, after due diligence we discovered either inadequate technology or unfavorable business terms for our shareholders. This area remains a high priority and we will continue to seek favorable acquisitions. We are also expanding staff and outsourcing some activities in order to enhance and expand our product lines.”

The Company has announced an earnings conference call for Friday, January 14, at 11:00 EST, which can be joined by going to: For listen-only mode, dial 516-453-0014 and enter access code 481-048-688.

About Simulations Plus, Inc.

Simulations Plus, Inc. is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed and used worldwide by major pharmaceutical and biotechnology companies for drug research and in the study of environmental toxicology. We also provide a productivity tool called Abbreviate! for PCs and the Apple iPhone as well as an educational software series for science students in middle and high schools known as FutureLab. Our wholly owned subsidiary, Words+, Inc., provides assistive technologies to persons with disabilities. Simulations Plus, Inc. is headquartered in Southern California and trades on the NASDAQ Capital Market under the symbol “SLP.” For more information, visit our Web sites at and

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the Securities and Exchange Commission.

Condensed Consolidated Balance Sheets
at November 30, 2010 (Unaudited) and August 31, 2010 (Audited)
November 30, August 31,
2010 2010
Current assets
Cash and cash equivalents $ 8,873,080 $ 9,631,762
Income tax refund receivable 259,434 225,510
Accounts receivable, net of allowance for doubtful accounts
and estimated contractual discounts of $395,358 and $421,118 1,537,713 1,291,350
Contracts receivable 166,669 184,081
Inventory 522,478 554,867
Prepaid expenses and other current assets 105,193 138,163
Deferred income taxes 310,024 364,264
Total current assets 11,774,591 12,389,997
Capitalized computer software development costs,
net of accumulated amortization of $4,674,008 and $4,487,757 2,187,458 2,186,419
Property and equipment, net 75,364 55,984
Customer relationships, net of accumulated amortization of $120,935 and $118,442 7,107 9,600
Other assets 18,445 18,445
Total assets $ 14,062,965 $ 14,660,445
Current liabilities
Accounts payable $ 309,480 $ 239,424
Accrued payroll and other expenses 506,632 511,106
Accrued bonuses to officer 103,402 60,000
Accrued income taxes 102,914 261,861
Accrued warranty and service costs 39,605 35,586
Deferred revenue 33,170 96,092
Total current liabilities 1,095,203 1,204,069
Long-term liabilities
Deferred income taxes 486,072 410,523
Total liabilities 1,581,275 1,614,592
Commitments and contingencies
Shareholders’ equity
Preferred stock, $0.001 par value
10,000,000 shares authorized
no shares issued and outstanding
Common stock, $0.001 par value
50,000,000 shares authorized
15,501,979 and 15,833,006 shares issued and outstanding 3,973 4,304
Additional paid-in capital 4,759,943 5,891,268
Retained earnings 7,717,774 7,150,281
Total shareholders’ equity 12,481,690 13,045,853
Total liabilities and shareholders’ equity $ 14,062,965 $ 14,660,445
Condensed Consolidated Statements of Operations
For the three months ended November 30
2010 2009
Net sales $ 2,811,286 $ 2,437,052
Cost of sales 740,983 606,889
Gross profit 2,070,303 1,830,163
Operating expenses
Selling, general, and administrative 1,062,375 1,004,273
Research and development 208,039 261,325
Total operating expenses 1,270,414 1,265,598
Income from operations 799,889 564,565
Other income (expense)
Interest income 24,641 22,486
Miscellaneous income 231 231
Gain on currency exchange 73,232
Gain on sale of assets 1,024
Interest expense (118 ) (302 )
Total other income (expense) 24,754 96,671
Income before income taxes 824,643 661,236
Provision for income taxes (257,150 ) (231,433 )
Net income $ 567,493 $ 429,803
Basic earnings per share $ 0.04 $ 0.03
Diluted earnings per share $ 0.03 $ 0.03
Weighted-average common shares outstanding
Basic 15,691,345 15,648,630
Diluted 16,525,142 16,775,287

Simulations Plus Investor Relations

Ms. Renée Bouché



Hayden IR

Mr. Cameron Donahue


Friday, January 14th, 2011 Uncategorized
Top Small Cap Market News